Sarcomatoid mesothelioma

D2-40

Podoplanin

Calretinin

TTF-1

MOC31

Vimentin

CK5/6

WT-1

Thrombomodulin

HMBE1

SMA

Pan CK(using cocktail of AE1/AE3, Cam5.2 and CK904)

Mesothelioma

epithelioid

17/18(13/13 full sections, 4/5 TMAs)1

40/46(32/36 full sections, 8/10 TMAs)1

16/221, 16/16(staining was strong and diffuse, both nuclear and cytoplasmic in all cases)2

0/121

4/51

4/121

16/16(all cases strongly and, in 13 cases, diffusely positive)2

11/162

13/162

8/16(less intense than in the sarcomatoid mesotheliomas)2

16/16(all cases strongly and diffusely positive)2

biphasic

10/12(9/11 full sections, 1/1 TMAs: staining was more intense in the epithelioid areas)

11/13(10/12 full sections, 1/1 TMAs: staining was more intense in the epithelioid areas)

5/9(ony 2 of the 5 positive cases showed staining of the sarcomatoid areas)

0/11

0/11

0/11

epithelioid component of biphasic

9/10(staining was strong and diffuse, both nuclear and cytoplasmic in all positive cases)2

4/102

6/102

9/102

2/10(less intense than in the sarcomatoid component)2

10/10(all cases strongly and diffusely positive)2

sarcomatoid component of biphasic

6/10(staining was both nuclear and cytoplasmic in all positive cases bu tless intense than in the epithelioid component)2

1/102

2/102

5/10(less intense than in the epithelioid component)2

6/102

9/10(less strongly positive than the epithelioid component)2

sarcomatoid

11/15(9/10 full sections, 2/4 TMAs: cytoplasmic staining in 10% to 50% of tumour cells)1

13/18(8/10 full sections, 5/8 TMAs: cytoplasmic staining in 10% to 50% of tumour cells)1

6/141, 7/10(staining was both nuclear and cytoplasmic in all positive cases but less intense than in the epithelioid mesotheliomas)2, 12/31(focal)3, 4/84, 3/35, 7/76, 4/84, 7/87  

0/81

0/41

7/81

0/102, 9/313, 1/7(focal)6, 1/87

1/102, 0/46, 4/84, 1/87

7/10(less intense than in the epithelioid mesotheliomas and with a cytoplasmic distribution)2, 9/313, 5/7(focal)6, 1/87

0/76, 3/84

6/102

7/10(less strongly positive than the epithelioid mesotheliomas: the three negative cases were negative for CK5/6 and CK7 as well)2, 24/313 

Pulmonary adenocarcinoma

2/80(using TMAs: in addition, squamoid foci stained)1

0/80(using TMAs: in addition, squamoid foci stained)1

3/801

61/801

77/801

4/801

Sarcomatoid carcinoma

1/13(using TMAs: weak staining in one laryngeal carcinoma)1

1/15(using TMAs)1

0/161, 6/102, 0/43

0/161

6/161

9/161

0/102, 0/43

0/102

4/102, 0/43

1/102

9/10(intense staining of 5% or more of tumour cells)2, 4/43

Sarcomas

1/8(Synovial sarcoma: using full sections: ytoplasmic staining in 1 case)1

0/8(Synovial sarcoma: using full sections)1

2/7(Synovial sarcoma)1, 4/24(1/1 MFH, 1/5 leiomyosarcomas, 1/2 synovial sarcomas, 0/2 osteosarcomas, 1/1 fibrosarcoma, 0/1 GIST, 0/1 epithelioid sarcoma, 0/1 myofibroblastic sarcoma)2, 0/303

0/7(Synovial sarcoma)1

3/7(Synovial sarcoma)1

6/7(Synovial sarcoma: the negative case was almost exclusively epithelioid)1

1/24(0/11 MFH, 0/5 leiomyosarcomas, 0/2 synovial sarcomas, 0/2 osteosarcomas, 0/1 fibrosarcoma, 0/1 GIST, 1/1 epithelioid sarcoma, 0/1 myofibroblastic sarcoma)2, 1/30(0/2 synovial sarcomas, 0/2 mixed Mullerian tumours, 0/3 leiomyosarcomas, 1/9 sarcoma NOS, 0/4 MPNST, 0/3 angiosarcomas, 0/1 chondrosarcoma, 0/1 Askin tumour,)3

1/24(0/1 MFH, 1/5 leiomyosarcomas, 0/2 synovial sarcomas, 0/2 osteosarcomas, 0/1 fibrosarcoma, 0/1 GIST, 0/1 epithelioid sarcoma, 0/1 myofibroblastic sarcoma)2

9/24(1 MFH, 5 leiomyosarcomas, 2 synovial sarcomas, 2 osteosarcomas, 1 fibrosarcoma, 1 GIST, 1 epithelioid sarcoma, 1 myofibroblastic sarcoma)2, 4/30(0/2 synovial sarcomas, 0/2 mixed Mullerian tumours, 0/3 leiomyosarcomas, 2/9 sarcoma NOS, 0/4 MPNST, 2/3 angiosarcomas, 0/1 chondrosarcoma, 0/1 Askin tumour,)3

14/24(1 MFH, 5 leiomyosarcomas, 2 synovial sarcomas, 2 osteosarcomas, 1 fibrosarcoma, 1 GIST, 1 epithelioid sarcoma, 1 myofibroblastic sarcoma)2

4/24(0/1 MFH, 1/5 leiomyosarcomas, 1/2 synovial sarcomas, 0/2 osteosarcomas, 1/1 fibrosarcoma, 0/1 GIST, 1/1 epithelioid sarcoma, 0/1 myofibroblastic sarcoma)2, 7/30(2/2 synovial sarcomas, 2/2 mixed Mullerian tumours, 1/3 leiomyosarcomas, 2/9 sarcoma NOS, 0/4 MPNST, 0/3 angiosarcomas, 0/1 chondrosarcoma, 0/1 Askin tumour,)3